Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas

The revised WHO classification newly defined the entities “High‐grade B‐cell lymphoma with MYC and BCL2, and/or BCL6 rearrangements (HGBL‐DH/TH)” and “HGBL, NOS.” Standard immunochemotherapy for diffuse large B‐cell lymphoma (DLBCL), R‐CHOP, is insufficient for HGBL patients, and there are currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yuka, Momose, Shuji, Tabayashi, Takayuki, Sawada, Keisuke, Yamashita, Takahisa, Higashi, Morihiro, Sagawa, Morihiko, Tokuhira, Michihide, Rosenwald, Andreas, Kizaki, Masahiro, Tamaru, Jun‐ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004541/
https://www.ncbi.nlm.nih.gov/pubmed/31849147
http://dx.doi.org/10.1111/cas.14286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004541/
https://www.ncbi.nlm.nih.gov/pubmed/31849147
http://dx.doi.org/10.1111/cas.14286

Ejemplares similares